Atlanta, GA – Scibility Media – 10/30/2014.
This article discusses two companies: Rock Creek Pharmaceuticals Inc(NASDAQ:RCPI) and Aerohive Networks Inc(NYSE:HIVE)
Rock Creek Pharmaceuticals Inc(NASDAQ:RCPI) was forced to suspend its CigRx and Anatabloc products due to the fact that one of its primary ingredients, anatabine, requires FDA approval before it can be marketed. The company’s fortunes, however, may soon change. Four individuals from the independent Roskamp Institute, a not-for-profit organization, will be presenting four anatabine projects at the annual meeting of the Society for Neuroscience, which will be held from Nov. 15th to Nov. 19th in Washington, DC.
The company, which was previously known as Star Scientific, had been marketing its Anatabloc product for the treatment of ulcerative colitis, multiple sclerosis, and Alzheimer’s disease. A Nov. 17th presentation by Megha Varma will address the “Effects of anatabine on Alzheimer’s disease (AD) like pathology, neuroinflammation and behavior in transgenic mouse model of AD.”
Aerohive Networks Inc(NYSE:HIVE) is a California-based communications equipment company that designs and develops a cloud-managed mobile network platform. The company announced on Oct. 28th that it had been selected by Apple to provide Wi-Fi infrastructure that will support a $100 million contribution to ConnectED, a government initiative to help teachers access the best technology.
In an effort to support the initiative, Apple will be providing ConnectED with iPads, MacBooks, and Apple TVs to over 114 schools. Aerohive’s Wi-Fi infrastructure will support Apple’s deployments, providing access to content and curriculum through 802.11ac wireless access points and cloud-based management. The company has a market capitalization of over $250 million.
EquiPress.com is a non-advertisement based network (currently in limited release) designed for investors to discover and communicate with publicly traded companies in real-time.
Sign-up for free now to experience the full benefits of EquiPress pre-launch.
Discover and communicate with companies you would otherwise never have seen based on your interests, company news, personalized news feeds, and one-on-one communications with no middle-men nor advertisements. Read our no advertisements pledge.
Can’t find your company on EquiPress? Send us an email to firstname.lastname@example.org and we will contact them for you.
Interested in a one month free trial? Get access to our private investor network, real-time news distribution, automatic disclaimers, corporate analytics, verified public profile, and industry-wide marketing of your corporate news.
Disclosure: EquiPress is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. EquiPress does not hold any equity or financial interest in any publicly traded company. EquiPress provides a uniform subscription based service to all publicly traded companies on a monthly basis at a rate of $495 to provide investor awareness. EquiPress receives only cash compensation from clients. Despite the relationship, EquiPress maintains a neutral stance (nonbiased) on any investment related opinions and exists solely for the purpose of allowing investors to communicate with the publicly traded companies in an effort to establish for themselves investment considerations. Investors should always conduct their own due diligence with any potential investment. Always seek help from a professional financial advisor. Please visit www.equipress.com for complete risks and disclosures.